

Discure - Reversing Disc Degeneration

Yuval Mandelbaum

Company name- Discure Technologies * Website-
<https://il.linkedin.com/company/discuretechnologies> *

CEO name-Yuval Mandelbaum*

CATEGORY: Medical Devices * SESSIONS • Is it time to celebrate the rebound of the medical device sector?

o Executive Summary / Investment Rational Briefly describe the company's technology or therapeutic focus; the market opportunity, progress made to date, key partnerships or joint ventures, investment to date; and management strengths. Discure is developing a unique solution to treat and reverse degenerative disc disease (DDD), one of the most significant unmet medical needs today, with a total addressable market of over \$15B. The company is backed by international VCs and tier-A strategics, has received FDA Breakthrough Device Designation, and has received multiple international awards. Clinical studies are in progress.

o Core Technology What is the technology, its uniqueness, and its value proposition? Unlike existing symptom-masking treatments like opioids or surgery, Discure is a minimally invasive, implantable bioelectronic device that treats and reverses Degenerative Disc Disease, by electrically restoring the disc's healthy fluid dynamics, allowing restoration of cushioning and stability to the spine, reviving the disc's cell population and accelerating tissue healing to reduce pain and restore function.

o Product Profile/Pipeline Briefly describe the company's product/pipeline, status, and market potential. Discuss milestones, potential collaborations, and partnerships. Discure is a platform technology with the potential to treat multiple indications across orthopedics, including multiple spinal disorders as well as disorders of synovial joints such as the hip, shoulder and Knee.

o Business Strategy Briefly describe how the company will apply its core technology, generate shortterm and long-term revenues. Discure offers the first treatment with the potential to heal the disc, rather than only mask the symptoms of degeneration. This is accomplished via a short outpatient procedure, performed under local anesthesia.

o What's Next? R&D, Preclinical / Clinicals, Organizational Plans, Financial Plans The company has run multiple pre-clinical studies in various in-vivo and ex-vivo models in the US, EU and Israel. The company is now initiating its first-in-human in the EU and North-America.